SK283711B6 - Liečivo na liečenie úzkosti a panického strachu - Google Patents

Liečivo na liečenie úzkosti a panického strachu Download PDF

Info

Publication number
SK283711B6
SK283711B6 SK90-97A SK9097A SK283711B6 SK 283711 B6 SK283711 B6 SK 283711B6 SK 9097 A SK9097 A SK 9097A SK 283711 B6 SK283711 B6 SK 283711B6
Authority
SK
Slovakia
Prior art keywords
gabapentin
test
anxiety
effects
treatment
Prior art date
Application number
SK90-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK9097A3 (en
Inventor
Geoffrey Neil Woodruff
Nicolas Steven Gee
Lakhbir Singh
Jason Peter Brown
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/445,398 external-priority patent/US5792796A/en
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of SK9097A3 publication Critical patent/SK9097A3/sk
Publication of SK283711B6 publication Critical patent/SK283711B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SK90-97A 1994-07-27 1995-07-11 Liečivo na liečenie úzkosti a panického strachu SK283711B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28128594A 1994-07-27 1994-07-27
US08/445,398 US5792796A (en) 1994-07-27 1995-06-06 Methods for treating anxiety and panic
PCT/US1995/008702 WO1996003122A2 (en) 1994-07-27 1995-07-11 Use of gabapentin in the treatment of anxiety and panic

Publications (2)

Publication Number Publication Date
SK9097A3 SK9097A3 (en) 1998-05-06
SK283711B6 true SK283711B6 (sk) 2003-12-02

Family

ID=26960801

Family Applications (1)

Application Number Title Priority Date Filing Date
SK90-97A SK283711B6 (sk) 1994-07-27 1995-07-11 Liečivo na liečenie úzkosti a panického strachu

Country Status (18)

Country Link
EP (1) EP0804182B1 (es)
JP (1) JPH10503490A (es)
AT (1) ATE218334T1 (es)
AU (1) AU703428B2 (es)
CA (1) CA2193384C (es)
CZ (1) CZ291757B6 (es)
DE (1) DE69526972T2 (es)
DK (1) DK0804182T3 (es)
ES (1) ES2176334T3 (es)
HU (4) HU0102041D0 (es)
MX (1) MX9606674A (es)
NZ (1) NZ290050A (es)
PL (1) PL187064B1 (es)
PT (1) PT804182E (es)
RO (1) RO120041B1 (es)
RU (1) RU2168982C2 (es)
SK (1) SK283711B6 (es)
WO (1) WO1996003122A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712158A (en) * 1995-06-06 1998-01-27 Warner-Lambert Company Cell line for the rapid expression of functional calcium channels
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
PL199794B1 (pl) 1997-10-27 2008-10-31 Warner Lambert Co Związki pośrednie do wytwarzania pochodnych cyklicznych aminokwasów
JP2002516312A (ja) * 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー カルシウムチャンネルのα２δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
CA2384911C (en) * 1999-09-16 2008-07-22 Warner-Lambert Company Method for the screening of .alpha.2. delta.-1 subunit binding ligands
RU2377234C2 (ru) * 2003-09-17 2009-12-27 Ксенопорт, Инк. Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016465A1 (en) * 1989-06-02 1990-12-02 Zola Phillip Horovitz Method for preventing or treating anxiety employing a calcium channel blocker
US5189026A (en) * 1991-06-07 1993-02-23 Fractal Laboratories, Inc. Treatment of human diseases involving dysregulation or dysfunction of the nervous system
EP0641330B1 (en) * 1992-05-20 2001-10-17 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment

Also Published As

Publication number Publication date
HU0102041D0 (en) 2001-07-30
AU3006995A (en) 1996-02-22
JPH10503490A (ja) 1998-03-31
AU703428B2 (en) 1999-03-25
ES2176334T3 (es) 2002-12-01
CA2193384A1 (en) 1996-02-08
CZ291757B6 (cs) 2003-05-14
HU223841B1 (hu) 2005-02-28
HU0102043D0 (en) 2001-07-30
MX9606674A (es) 1997-03-29
SK9097A3 (en) 1998-05-06
DK0804182T3 (da) 2002-09-09
NZ290050A (en) 1999-08-30
EP0804182B1 (en) 2002-06-05
CA2193384C (en) 2002-03-19
PL318268A1 (en) 1997-05-26
PT804182E (pt) 2002-10-31
DE69526972D1 (de) 2002-07-11
WO1996003122A3 (en) 1996-07-18
RO120041B1 (ro) 2005-08-30
RU2168982C2 (ru) 2001-06-20
PL187064B1 (pl) 2004-05-31
WO1996003122A2 (en) 1996-02-08
DE69526972T2 (de) 2002-11-21
CZ16297A3 (en) 1997-07-16
ATE218334T1 (de) 2002-06-15
HU0102040D0 (en) 2001-07-30
EP0804182A2 (en) 1997-11-05
HUT76835A (en) 1997-11-28

Similar Documents

Publication Publication Date Title
Vas et al. Eburnamine derivatives and the brain
DE69930552T2 (de) Exo-s-mecamylamin-formulierung und ihre verwendung in behandlungen
KR100758609B1 (ko) 트라마돌 화합물 및 항경련 약물을 포함하는 조성물
US20050222093A1 (en) Methods for restoring cognitive function following systemic stress
Łątka et al. γ-Aminobutyric acid transporters as relevant biological target: Their function, structure, inhibitors and role in the therapy of different diseases
Palmer et al. Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide
HUE033180T2 (en) Peptide compounds for the treatment of difficult to cure epileptic diseases
US5792796A (en) Methods for treating anxiety and panic
Lagos et al. Paralytic shellfish poisoning (PSP): toxicology and kinetics
SK283711B6 (sk) Liečivo na liečenie úzkosti a panického strachu
Marquis et al. Animal models of intravenous phencyclinoid self-administration
KR102269493B1 (ko) (r)-디미라세탐 (1) 및 (s)-디미라세탐 (2)을 비-라세미 비로 포함하는 상승작용적 조성물
SK117794A3 (en) Enatiomeric 1-phenyl-2-(2-pyridinyl)ethylamene for the treatment of neurogenerative disorders
Löscher et al. Effects of the competitive NMDA receptor antagonist, CGP 37849, on anticonvulsant activity and adverse effects of valproate in amygdala-kindled rats
Heinemann et al. 4. In vitro epileptiform activity: role of excitatory amino acids
Swinyard et al. Characterization of the anticonvulsant properties of F-721
Windisch COGNITION-ENHANCING
JPH03209355A (ja) アリールアルキルアミド含有の神経変性疾患治療剤
AU735816B2 (en) Use of gabapentin in the treatment of anxiety and panic
EP1755583B1 (en) Use of neboglamine for the treatment of schizophrenia
Sharma et al. Experimental study on antiepileptic action of Kousheyashma Bhasma
KR20210099567A (ko) (r)-2-(2-옥소피롤리딘-1-일)부탄아미드 및 (s)-2-(2-옥소피롤리딘-1-일)부탄아미드를 비-라세미 비로 포함하는 상승작용적 조성물
NZ336674A (en) Use of gabapentin in the treatment of anxiety and panic
KR20210099566A (ko) R-2-(치환된-술포닐)-헥사히드로-피롤로[1,2-a]피라진-6(2H)-온 및 S-2-(치환된-술포닐)-헥사히드로-피롤로[1,2-a]피라진-6(2H)-온을 비-라세미 비로 포함하는 상승작용적 조성물
Allen A review of the actions of d-cycloserine, a putative nootropic agent, at the NMDA receptor complex-associated glycine binding site